Craft
Biogen

Biogen

Patients (Biosimilars, Europe)

253 K

Q2, 2022

Revenue

$11 B

FY, 2021

Market Capitalization

$41.9 B

2023-01-11

Biogen Summary

Company summary

Overview
Biogen is a biotechnology company that discovers, develops, and delivers therapies for people living with serious neurological and neurodegenerative diseases. It is primarily focused on developing medicines to treat multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. The company also manufactures and commercializes biosimilars of advanced biologics.
Type
Public
Status
Active
Founded
1978
HQ
Cambridge, MA, US | view all locations
Website
https://www.biogen.com
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key people

  • Michel Vounatsos

    Michel Vounatsos, Chief Executive Officer and Director

  • Stelios Papadopoulos

    Stelios Papadopoulos, Chairman of the Board

    • Susan Alexander

      Susan Alexander, Chief Legal Officer and Secretary

    • Michael McDonnell

      Michael McDonnell, Chief Financial Officer

      Operating MetricsView all

      Floor Space Owned (RTP, North Carolina), sq. ft.

      1M

      FY, 2021

      Warehouse Facilities Leased (Durham, North Carolina), sq. ft.

      65K

      FY, 2021

      Products (Multiple Sclerosis and Neuroimmunology)

      6

      FY, 2021

      LocationsView all

      46 locations detected

      • Cambridge, MA HQ

        United States

        225 Binney St

      • Morrisville, NC

        United States

        5000 Davis Dr

      • Waltham, MA

        United States

        203 Crescent St #303

      • Washington, DC

        United States

        701 Pennsylvania Avenue NW #715

      • Weston, MA

        United States

        133 Boston Post Rd

      • Vicente López, Buenos Aires

        Argentina

        7th Floor, Av. del Libertador 350

      and 40 others

      Biogen Financials

      Summary financials

      Revenue (Q3, 2022)
      $2.5B
      Gross profit (Q3, 2022)
      $2.0B
      Net income (Q3, 2022)
      $1.1B
      Cash (Q3, 2022)
      $3.7B
      Enterprise value
      $44.8B

      Footer menu